Document:

exv10w1

 

Exhibit 10.1

Form of Subscription Agreement

SUBSCRIPTION AGREEMENT

April 11, 2007

Gentlemen:

The undersigned (the “Investor”) hereby confirms its agreement with you as follows:

1. This Subscription Agreement (this “Agreement”) is made as of the date set forth
below between Cell Genesys, Inc., a Delaware corporation (the “Company”), and the
Investor.

2. The Company has authorized the sale and issuance to certain investors of up to an
aggregate of 10,810,811 units (the “Units”), each consisting of (i) one (the “Share,”
collectively, the “Shares”) of its common stock, par value $0.001 per share (the
“Common Stock”), and (ii) one warrant (“Warrant,” collectively, the “Warrants”) to
purchase 0.20 shares of Common Stock (and the fractional amount being the “Warrant
Ratio”), subject to adjustment by the Company’s Board of Directors, or a committee
thereof, for a purchase price of $5.55 per Unit (the “Purchase Price”). The Shares
issuable upon exercise of the Warrants are referred to herein as “Warrant Shares”
and, together with the Units, the Shares and the Warrants, are collectively referred
to herein as the “Securities.”

3. The offering and sale of the Units (the “Offering”) is being made pursuant to (1)
an effective Registration Statement on Form S-3 (Registration No. 333-102122) filed
by the Company with the Securities and Exchange Commission (the “Commission”) and an effective Registration Statement on Form S-3
dated April 11, 2007 filed by the Company with the SEC pursuant to Rule 462(b) of the Act, (collectively, the
“Registration Statement”), which contains the base prospectus dated February 6, 2003
(the “Base Prospectus”), (2) if applicable, certain “free writing prospectuses” (as
that term is defined in Rule 405 under the Securities Act of 1933, as amended), that
have or will be filed with the Commission and delivered to the Investor on or prior
to the date hereof, (3) a preliminary prospectus supplement to the Base Prospectus
dated April 10, 2007 (the “Preliminary Prospectus”), and (4) a final prospectus
supplement (the “Prospectus Supplement” and together with the Base Prospectus, the
“Prospectus”) containing certain supplemental information regarding the Units and
terms of the Offering that will be filed with the Commission and delivered to the
Investor (or made available to the Investor by the filing by the Company of an
electronic version thereof with the Commission) along with the Company’s counterpart
to this Agreement.

4. The Company and the Investor agree that the Investor will purchase from the
Company and the Company will issue and sell to the Investor the Units set forth
below for the aggregate purchase price set forth below. The Units shall be
purchased pursuant to the Terms and Conditions for Purchase of Units attached

Page 1

 

hereto as Annex I and incorporated herein by this reference as if fully set forth
herein. The Investor acknowledges that the Offering is not being underwritten by
the placement agents (the “Placement Agents”) named in the Prospectus Supplement and
that there is no minimum offering amount.

5. The manner of settlement of the Shares included in the Units purchased by the
Investor shall be determined by such Investor as follows:

	 	Delivery by electronic book-entry at The Depository Trust Company (“DTC”), registered in
the Investor’s name and address as set forth below, and released by Computershare Trust
Company, N.A., the Company’s transfer agent (the
“Transfer Agent”) (attention: Debra L. Kelley,
telephone: (781) 595-3788), to the Investor at the
Closing (as defined in Section 3.1 of Annex A hereto). NO LATER THAN ONE (1) BUSINESS DAY
AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, THE INVESTOR SHALL:
	 
	 	(I)	 	DIRECT THE BROKER-DEALER AT WHICH THE ACCOUNT OR ACCOUNTS TO BE CREDITED
WITH THE SHARES ARE MAINTAINED TO SET UP A DEPOSIT/WITHDRAWAL AT CUSTODIAN (“DWAC”)
INSTRUCTING THE TRANSFER AGENT TO CREDIT SUCH ACCOUNT OR ACCOUNTS WITH THE SHARES,
AND
	 
	 	(II)	 	REMIT BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE AGGREGATE PURCHASE
PRICE FOR THE UNITS BEING PURCHASED BY THE INVESTOR TO THE FOLLOWING ACCOUNT:

JPMorgan Chase Bank, N.A.

ABA Routing No. 021000021

Account No. 304-889-172, Cell Gen/Credit Suisse Sec. Escrow Agreement

Attn: Audrey Mohan

Phone: (212) 623-6811

IT IS THE INVESTOR’S RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER OR
CONFIRM THE PROPER ACCOUNT BALANCE IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT
BY WAY OF DWAC IN A TIMELY MANNER. IF THE INVESTOR DOES NOT DELIVER THE AGGREGATE
PURCHASE PRICE FOR THE UNITS OR DOES NOT MAKE PROPER ARRANGEMENTS FOR SETTLEMENT IN
A TIMELY MANNER, THE UNITS MAY NOT BE DELIVERED AT CLOSING TO THE INVESTOR OR THE
INVESTOR MAY BE EXCLUDED FROM THE CLOSING ALTOGETHER.

6. The executed Warrant shall be delivered in accordance with the terms set forth in
Annex I hereto.

Page 2

 

7. The Investor represents that, except as set forth below, (a) it has had no
position, office or other material relationship within the past three years with the
Company or persons known to it to be affiliates of the Company, (b) it is not a NASD
member or an Associated Person (as such term is defined under the NASD Membership
and Registration Rules Section 1011) as of the Closing, and (c) neither the Investor
nor any group of Investors (as identified in a public filing made with the
Commission) of which the Investor is a part in connection with the Offering of the
Units, acquired, or obtained the right to acquire, 20% or more of the Common Stock
(or securities convertible into or exercisable for Common Stock) or the voting power
of the Company on a post-transaction basis. Exceptions:

(If no exceptions, write “none.” If left blank, response will be deemed to be
“none.”)

8. The Investor represents that it has received or can obtain on the SEC’s Edgar
filing system the Base Prospectus, which is part of the Company’s Registration
Statement, the Preliminary Prospectus, the documents incorporated by reference
therein, and any free writing prospectus (collectively, the “Disclosure Package”),
prior to or in connection with the receipt of this Agreement along with the
Company’s counterpart to this Agreement.

9. No offer by the Investor to buy Units will be accepted and no part of the
Purchase Price will be delivered to the Company until the Company has accepted such
offer by countersigning a copy of this Agreement, and any such offer may be
withdrawn or revoked, without obligation or commitment of any kind, at any time
prior to the Company (or a Placement Agent on behalf of the Company) sending
(orally, in writing, or by electronic mail) notice of its acceptance of such offer.
An indication of interest will involve no obligation or commitment of any kind until
this Agreement is accepted and countersigned by or on behalf of the Company.

Number of Units:

Purchase Price Per Unit: $

Aggregate Purchase Price: $

Page 3

 

Please confirm that the foregoing correctly sets forth the agreement between us by
signing in the space provided below for that purpose.

	 	 	 	 	 
	 	 	Dated as of: April 11, 2007
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 
	 

	 	INVESTOR	 	 
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Print	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	 

Agreed and Accepted

this                                          day of                                         , 2007:

CELL GENESYS, INC.

By:                                         

Title:

Page 4

 

ANNEX I TO EXHIBIT A

TERMS AND CONDITIONS FOR PURCHASE OF UNITS

1. Authorization and Sale of the Units. Subject to the terms and conditions of this
Agreement, the Company has authorized the sale of the Units.

2. Agreement to Sell and Purchase the Units; Placement Agents.

2.1 At the Closing (as defined in Section 3.1), the Company will sell to the
Investor, and the Investor will purchase from the Company, upon the terms and
conditions set forth herein, the number of Units set forth on the last page of the
Agreement to which these Terms and Conditions for Purchase of Units are attached as
Annex I (the “Signature Page”) for the aggregate purchase price therefor set forth
on the Signature Page.

2.2 The Company proposes to enter into substantially this same form of Subscription
Agreement with certain other investors (the “Other Investors”) and expects to
complete sales of Units to them. The Investor and the Other Investors are
hereinafter sometimes collectively referred to as the “Investors,” and this
Agreement and the Subscription Agreements executed by the Other Investors are
hereinafter sometimes collectively referred to as the “Agreements.”

2.3 Investor acknowledges that the Company intends to pay Credit Suisse Securities
(USA) LLC, Needham & Company, LLC, Canaccord Adams Inc. and Cantor Fitzgerald & Co. (collectively, the
“Placement Agents”) a fee (the “Placement Fee”) in respect of the sale of Units to
the Investor.

2.4 The Company has entered into a Placement Agency Agreement, dated April 11, 2007
(the “Placement Agreement”), with the Placement Agents that contains certain
representations, warranties, covenants, and agreements of the Company that may be
relied upon by the Investor, which shall be a third party beneficiary thereof. A
copy of the Placement Agreement is available upon request.

3. Closings and Delivery of the Units and Funds.

3.1 Closing. The completion of the purchase and sale of the Units (the “Closing”)
shall occur at a place and time (the “Closing Date”) to be specified by the Company
and the Placement Agents, and of which the Investors will be notified in advance by
the Placement Agents, in accordance with Rule 15c6-1 promulgated under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”). At the Closing,
(a) the Company shall cause the Transfer

Annex I - Page 1

 

Agent to deliver to the Investor the number of Shares set forth on the Signature
Page registered in the name of the Investor or, if so indicated on the Investor
Questionnaire attached hereto as Schedule A, in the name of a nominee designated by
the Investor, (b) the Company shall cause to be delivered to the Investor a Warrant
to purchase a number of whole Warrant Shares determined by multiplying the number of
Shares set forth on the signature page by the Warrant Ratio and rounding down to the
nearest whole number and (c) the aggregate purchase price for the Units being
purchased by the Investor will be delivered by or on behalf of the Investor to the
Company.

3.2 (a) Conditions to the Company’s Obligations. The Company’s obligation to issue
and sell the Units to the Investor shall be subject to: (i) the receipt by the
Company of the purchase price for the Units being purchased hereunder as set forth
on the Signature Page and (ii) the accuracy of the representations and warranties
made by the Investor and the fulfillment of those undertakings of the Investor to be
fulfilled prior to the Closing Date.

(b) Conditions to the Investor’s Obligations. The Investor’s obligation to purchase
the Units will be subject to the accuracy of the representations and warranties made
by the Company and the fulfillment of those undertakings of the Company to be
fulfilled prior to the Closing Date those contained in the Placement Agreement and
the Subscription Agreement, and to the condition that the Placement Agents shall not
have: (i) terminated the Placement Agreement pursuant to the terms thereof or (ii)
determined that the conditions to the closing in the Placement Agreement have not
been satisfied. The Investor’s obligations are expressly not conditioned on the
purchase by any or all of the Other Investors of the Units that they have agreed to
purchase from the Company or the issuance of any minimum amount of Units by the
Company.

3.3 Delivery of Funds by Electronic Book-Entry at The Depository Trust Company.
No later than one (1) business day after the execution of this Agreement by the
Investor and the Company, the Investor shall remit by wire transfer the amount
of funds equal to the aggregate purchase price for the Units being purchased by the
Investor to the following account designated by the Company and the Placement Agents
pursuant to the terms of that certain Escrow Agreement (the “Escrow Agreement”)
dated as of April 11, 2007, by and among the Company, the Placement Agents and
JPMorgan Bank, N.A. (the “Escrow Agent”):

Annex I - Page 2

 

JPMorgan Chase Bank, N.A.

ABA Routing No. 021000021

Account No. 304-889-172, Cell Gen/Credit Suisse Sec. Escrow Agreement

Attn: Audrey Mohan

Phone: 212.623.6811

Such funds shall be held in escrow until the Closing and delivered by the Escrow
Agent on behalf of the Investors to the Company upon the satisfaction, in the
reasonable judgment of the Placement Agents, of the conditions set forth in Section
3.2(b) hereof. The Placement Agents shall have no rights in or to any of the
escrowed funds unless the Placement Agents and the Escrow Agent are notified in
writing by the Company in connection with the Closing that a portion of the escrowed
funds shall be applied to the Placement Fee as contemplated by Section 2(e) of the
Placement Agreement. The Company and the Investor agree to indemnify and hold the
Escrow Agent and the Placement Agents harmless from and against any and all losses,
costs, damages, expenses and claims (including, without limitation, court costs and
reasonable attorneys fees) (“Losses”) arising under this Section 3.3 or otherwise
with respect to the funds held in escrow pursuant hereto or arising under the Escrow
Agreement, unless it is finally determined that such Losses resulted directly from
the willful misconduct or gross negligence of the Escrow Agent or the Placement
Agents. Anything in this Agreement to the contrary notwithstanding, in no event
shall the Escrow Agent or the Placement Agents be liable for any special, indirect
or consequential loss or damage of any kind whatsoever (including but not limited to
lost profits), even if the Escrow Agent or the Placement Agents have been advised of
the likelihood of such loss or damage and regardless of the form of action.

3.4 Delivery of Shares by Electronic Book-Entry at The Depository Trust Company.
No later than one (1) business day after the execution of this Agreement by the
Investor and the Company, the Investor shall direct the broker-dealer at which
the account or accounts to be credited with the Shares being purchased by such
Investor are maintained, which broker/dealer shall be a DTC participant, to set up a
Deposit/Withdrawal at Custodian (“DWAC”) instructing Computershare Trust Company,
N.A., the Company’s transfer agent, to credit such account or accounts with the
Shares by means of an electronic book-entry delivery. Such DWAC shall indicate the
settlement date for the deposit of the Shares, which date shall be provided to the
Investor by the Placement Agents. Simultaneously with the delivery to the Company
by the Escrow Agent of the funds held in escrow pursuant to Section 3.3 above, the
Company shall direct its transfer agent to credit the Investor’s account or accounts
with the Shares pursuant to the information contained in the DWAC.

Annex I - Page 3

 

4. Representations, Warranties and Covenants of the Investor.

4.1 The Investor represents and warrants to, and covenants with, the Company that
(a) the Investor is knowledgeable, sophisticated and experienced in making, and is
qualified to make decisions with respect to, investments in shares presenting an
investment decision like that involved in the purchase of the Units, including
investments in securities issued by the Company and investments in comparable
companies, and has requested, received, reviewed and considered all information it
deemed relevant in making an informed decision to purchase the Units, (b) the
Investor has answered all questions on the Signature Page and the Investor
Questionnaire for use in preparation of the Prospectus Supplement and the answers
thereto are true and correct as of the date hereof and will be true and correct as
of the Closing Date and (c) the Investor, in connection with its decision to
purchase the number of Units set forth on the Signature Page, is relying only upon
the Disclosure Package and the representations and warranties of the Company
contained herein and the Placement Agency Agreement.

4.2 The Investor acknowledges, represents and agrees that no action has been or will
be taken in any jurisdiction outside the United States by the Company or the
Placement Agents that would permit an offering of the Units, or possession or
distribution of offering materials in connection with the issue of the Units in any
jurisdiction outside the United States where action for that purpose is required.
Each Investor outside the United States will comply with all applicable laws and
regulations in each foreign jurisdiction in which it purchases, offers, sells or
delivers Units or has in its possession or distributes any offering material, in all
cases at its own expense. The Placement Agents are not authorized to make and have
not made any representation or use of any information in connection with the issue,
placement, purchase and sale of the Units, except as set forth or incorporated by
reference in the Disclosure Package.

4.3 The Investor further represents and warrants to, and covenants with, the Company
that (a) the Investor has full right, power, authority and capacity to enter into
this Agreement and to consummate the transactions contemplated hereby and has taken
all necessary action to authorize the execution, delivery and performance of this
Agreement, and (b) this Agreement constitutes a valid and binding obligation of the
Investor enforceable against the Investor in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors’ and contracting parties’ rights
generally and except as enforceability may be subject to general principles of
equity (regardless of whether such enforceability is considered in a proceeding in
equity or at law) and except as the indemnification agreements of the Investors
herein may be legally unenforceable.

Annex I - Page 4

 

4.4 The Investor understands that nothing in this Agreement, the Prospectus or any
other materials presented to the Investor in connection with the purchase and sale
of the Units constitutes legal, tax or investment advice. The Investor has
consulted such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of Units.

4.5 Each Investor represents, warrants and agrees that, since the earlier to occur
of (i) the date on which any Placement Agent first contacted such Investor about the
Offering and (ii) the date of this Agreement, it has not engaged in any transactions
in the securities of the Company (including, without limitation, any Short Sales
involving the Company’s securities). Each Investor covenants that it will not
engage in any transactions in the securities of the Company (including Short Sales)
prior to the time that the transactions contemplated by this Agreement are publicly
disclosed. Each Investor agrees that it will not use any of the Units acquired
pursuant to this Agreement to cover any short position in the Common Stock if doing
so would be in violation of applicable securities laws. For purposes hereof, “Short
Sales” include, without limitation, all “short sales” as defined in Rule 200
promulgated under Regulation SHO under the Exchange Act, whether or not against the
box, and all types of direct and indirect stock pledges, forward sales contracts,
options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in
Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total
return basis), and sales and other transactions through non-US broker dealers or
foreign regulated brokers.

5. Survival of Representations, Warranties and Agreements; Third Party Beneficiary.
Notwithstanding any investigation made by any party to this Agreement or by the
Placement Agents, all covenants, agreements, representations and warranties made by
the Company and the Investor herein will survive the execution of this Agreement,
the delivery to the Investor of the Units being purchased and the payment therefor.
The Placement Agents shall be third party beneficiaries with respect to
representations, warranties and agreements of the Investor in Section 4 hereof.

6. Notices. All notices, requests, consents and other communications hereunder will
be in writing, will be mailed (a) if within the domestic United States by
first-class registered or certified airmail, or nationally recognized overnight
express courier, postage prepaid, or by facsimile or (b) if delivered from outside
the United States, by International Federal Express or facsimile, and will be deemed
given (i) if delivered by first-class registered or certified mail domestic, three
business days after so mailed, (ii) if delivered by nationally recognized overnight
carrier, one business day after so mailed, (iii) if delivered by International
Federal Express, two business days after so mailed and (iv) if delivered by

Annex I - Page 5

 

 facsimile, upon electric confirmation of receipt and will be delivered and addressed
as follows:

(a) if to the Company, to:

Cell Genesys, Inc.

500 Forbes Boulevard

South San Francisco, California 94080

Facsimile: (650) 266-3000

Attention: Chief Financial Officer

with copies to:

Wilson Sonsini Goodrich & Rosati Professional Corporation

650 Page Mill Road

Palo Alto, California 94304

Attention: Herbert P. Fockler, Esq.

Facsimile: (650) 493-6811

(b) if to the Investor, at its address on the Signature Page hereto, or at such
other address or addresses as may have been furnished to the Company in writing.

7. Changes. This Agreement may not be modified or amended except pursuant to an
instrument in writing signed by the Company and the Investor.

8. Headings. The headings of the various sections of this Agreement have been
inserted for convenience of reference only and will not be deemed to be part of this
Agreement.

9. Severability. In case any provision contained in this Agreement should be
invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein will not in any way be
affected or impaired thereby.

10. Governing Law. This Agreement will be governed by, and construed in accordance
with, the internal laws of the State of New York, without giving effect to the
principles of conflicts of law that would require the application of the laws of any
other jurisdiction.

11. Counterparts. This Agreement may be executed in two or more counterparts, each
of which will constitute an original, but all of which, when taken together, will
constitute but one instrument, and will become effective when one or more
counterparts have been signed by each party hereto and delivered to the other

Annex I - Page 6

 

 parties. The Company and the Investor acknowledge and agree that the Company shall
deliver its counterpart to the Investor along with the Base Prospectus and the
Prospectus Supplement (or the filing by the Company of an electronic version thereof
with the Commission).

12. Confirmation of Sale. The Investor acknowledges and agrees that such Investor’s
receipt of the Company’s counterpart to this Agreement, together with the Base
Prospectus and the Prospectus Supplement (or the filing by the Company of an
electronic version thereof with the Commission), shall constitute written
confirmation of the Company’s sale of Units to such Investor.

13. Press Release. The Company and the Investor agree that the Company shall issue
a press release announcing the material terms of the Offering prior to the opening of the financial
markets in New York City on the business day immediately after the date hereof.

14. Termination. In the event that the Placement Agreement is terminated by the
Placement Agents pursuant to the terms thereof, this Agreement shall terminate
without any further action on the part of the parties hereto.

Annex I - Page 7

 

SCHEDULE A TO ANNEX I

CELL GENESYS, INC.

INVESTOR QUESTIONNAIRE

	 	 	 	 	 
	 	 	Pursuant to Section 3 of Annex I to the Agreement, please provide us with the
following information:
	 
	 	 	 	 
	 
	 	 	 	 
	1.	 	The exact name that your Shares and Warrants are to be registered in. You may use a
nominee name if appropriate:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	2.	 	The relationship between the Investor and the registered holder listed in response to
item 1 above:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	3.	 	The mailing address of the registered holder listed in response to item 1 above:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	4.	 	The Social Security Number or Tax Identification Number of the registered holder
listed in the response to item 1 above:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

Schedule A to
Annex I-Page 1

 

	 	 	 	 	 
	5.	 	Name of DTC Participant (broker-dealer at which the account or accounts to be
credited with the Shares are maintained); please include the name and
telephone number of the contract person at the broker-dealer:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	6.	 	DTC Participant Number:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	7.	 	Name of Account at DTC Participant being credited with the Shares:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	8.	 	Account Number at DTC Participant being credited with the Shares:
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

Schedule A to
Annex I-Page 2exv10w1

 

Exhibit 10.1

Solectron Corporation

Remuneration for the CEO Search Committee of the Board of Directors

On March 6, 2007, the Board of Directors (the “Board”) of Solectron Corporation (the “Company”)
approved the following compensation for the members of the Board’s CEO Search Committee:

	 	 	 	 	 
	Dr. Paul R. Low (Chairman)
	 	$	20,000	 
	Heinz Fridrich
	 	$	11,000	 
	William A. Hasler
	 	$	11,000	 
	C. Wesley M. Scott
	 	$	11,000	 

These amounts are in addition to other remuneration and fees these directors are entitled to
receive as described in the Proxy Statement of the Company filed on December 4, 2006.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]